This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
DocuSign (DOCU) Dips 12% in 6 Months: Is the Stock Worth Buying?
by Shuvra Shankar Dey
Given the recent decline in DocuSign (DOCU) shares, we evaluate the stock's current position to determine whether it presents a good investment opportunity at this time.
MSFTNegative Net Change CRMPositive Net Change DOCUPositive Net Change
biotechnology tech-stocks
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
by Ekta Bagri
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
VRTXPositive Net Change PRMENegative Net Change CRSPNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
by Zacks Equity Research
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
TEVAPositive Net Change ANIPPositive Net Change ADPTNegative Net Change RAPTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
by Ekta Bagri
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
LXRXNegative Net Change SAVANegative Net Change LXEOPositive Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
by Zacks Equity Research
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
BAYRYNegative Net Change ANIPPositive Net Change ADPTNegative Net Change RAPTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
by Zacks Equity Research
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
ANIPPositive Net Change RARENegative Net Change ADPTNegative Net Change RAPTNegative Net Change
biotechnology biotechs medical pharmaceuticals
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
by Zacks Equity Research
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
JNJNegative Net Change BAYRYNegative Net Change ORICNo Net Change TRDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Amplify Energy (AMPY) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
AMPYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
by Zacks Equity Research
Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.
ANIPPositive Net Change ADPTNegative Net Change RAPTNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
by Zacks Equity Research
Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.
RHHBYNegative Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
AMSCPositive Net Change LINCPositive Net Change CORTPositive Net Change ADMAPositive Net Change BTMDNegative Net Change
biotechnology consumer-discretionary medical tech-stocks
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
ADPTNegative Net Change ACADNegative Net Change AXSMPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
ADPTNegative Net Change ACADNegative Net Change AXSMPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
by Zacks Equity Research
The FDA grants the Regenerative Medicine Advanced Therapy ("RMAT") designation to Kyvernas' (KYTX) lead candidate, KYV-101, for the treatment of patients suffering from refractory stiff-person syndrome.
CORTPositive Net Change NTLANegative Net Change TRDAPositive Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
by Zacks Equity Research
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
NVSNegative Net Change INCYPositive Net Change CORTPositive Net Change TRDAPositive Net Change
biotechnology biotechs pharmaceuticals
Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
by Zacks Equity Research
Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
BIIBPositive Net Change NVOPositive Net Change LLYPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
by Zacks Equity Research
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
MRKPositive Net Change IMMPNo Net Change ANVSNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for Fennec (FENC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Fennec (FENC) stock based on the movements in the options market lately.
FENCPositive Net Change
biotechnology biotechs medical
Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?
by Ekta Bagri
Bristol Myers (BMY) faces an uphill struggle as top drugs face challenges. We advise investors to steer clear for the time being.
BMYPositive Net Change PFEPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
by Zacks Equity Research
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
PCRXNegative Net Change CGENNegative Net Change ANVSNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
by Zacks Equity Research
Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.
INONegative Net Change CGENNegative Net Change ANVSNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Inflation Cools in June, Triggers Spike in Laggard ETFs
by Sweta Killa
June inflation data has deepened the market's confidence that the Fed would begin cutting interest rates in September, leading to a sector rotation from the hot technology sector to the laggards that could benefit from falling rates like industrials and small caps.
ITBNegative Net Change PBWNegative Net Change KREPositive Net Change BBCNegative Net Change IWCNegative Net Change
alt-energy biotechnology construction etfs finance
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ATATNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
by Zacks Equity Research
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.
SNYPositive Net Change QURENegative Net Change IDYANegative Net Change KYMRNegative Net Change HLVXNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals